Pharmacological mechanisms of berberine against triple negative breast cancer: Integration of network pharmacology and experimental validation
Phytomedicine Plus · 2025-08 · 5 (3) · 100694
DOI: 10.1016/j.phyplu.2024.100694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine Plus, 2025-08. Verfasst von Tian Qin und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guizhou Provincial Health and Family Planning Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Berberine (BBR) has garnered attention for its potential effectiveness against triple-negative breast cancer (TNBC). To further understand its pharmacological mechanisms, this study employed a combination of network pharmacology analysis and experimental verification for providing insights into the potential of BBR as a therapeutic option for TNBC.
Methods
Through an application of network pharmacology methods to foresee the essential targets and pathways of BBR in countering TNBC, an analysis of the protein-protein interaction (PPI) network, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was carried out. The confirmation of the bond between BBR and the target sites occurred via molecular docking utilizing CavityPlus and Autodock vina. To validate the outcomes of the network pharmacology analysis, experimental verification was performed through in vitro experiments.
Results
By searching the overlap between BBR and TNBC targets, a total of 257 potential targets were retrieved. PPI network analysis revealed that top of 15 targets as the pivotal gene. In the analysis of gene ontology (GO) enrichment results of effective target GO functional enrichment analysis suggested that BBR may be involved in protein phosphorylation and anti-apoptotic biological processes. The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis indicated that the anti-cancer effect of BBR was mediated by multiple pathways, such as pathways in cancer signaling pathways and apoptosis signaling pathways. The ''Compound-target-GO-pathway-disease'' network constructed and acetylation targets with molecular docking demonstrated the regulation of acetylation by BBR. Subsequently, in vitro assay results indicated that BBR, as an inhibitor of deacetyltransferase (KDACi), was capable of inhibiting the proliferation and migration of MDA-MB-231 cells and inducing cell apoptosis.
Conclusion
Through combining network pharmacology with vitro validation, this study identified BBR as a potential target of KDACi in TNBC, providing new insights into the pharmacology of acetylation in the treatment of TNBC.
Förderung
- Guizhou Provincial Health and Family Planning Commission
- National Natural Science Foundation of China
Zitieren
APA
Qin, T., Liu, K., Yang, Y., Huang, J., Chen, T., Jiang, Y., & Xu, S. (2025). Pharmacological mechanisms of berberine against triple negative breast cancer: Integration of network pharmacology and experimental validation. Phytomedicine Plus, 5(3), 100694. https://doi.org/10.1016/j.phyplu.2024.100694
Vancouver
Qin T, Liu K, Yang Y, Huang J, Chen T, Jiang Y, et al. Pharmacological mechanisms of berberine against triple negative breast cancer: Integration of network pharmacology and experimental validation. Phytomedicine Plus. 2025;5(3):100694. doi:10.1016/j.phyplu.2024.100694
BibTeX
@article{Qin2025,
author = {Qin, Tian and Liu, Kaixuan and Yang, Yushi and Huang, Jinjin and Chen, Tengxiang and Jiang, Yinhui and Xu, Shu},
title = {Pharmacological mechanisms of berberine against triple negative breast cancer: Integration of network pharmacology and experimental validation},
journal = {Phytomedicine Plus},
year = {2025},
volume = {5},
number = {3},
pages = {100694},
doi = {10.1016/j.phyplu.2024.100694}
}
EUVIMED